As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

Summary statistics for outcome and explanatory variables.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

As of June 13, 2023, there have been almost 768 million cases of coronavirus (COVID-19) worldwide. The disease has impacted almost every country and territory in the world, with the United States confirming around 16 percent of all global cases.

COVID-19: An unprecedented crisis Health systems around the world were initially overwhelmed by the number of coronavirus cases, and even the richest and most prepared countries struggled. In the most vulnerable countries, millions of people lacked access to critical life-saving supplies, such as test kits, face masks, and respirators. However, several vaccines have been approved for use, and more than 13 billion vaccine doses had already been administered worldwide as of March 2023.

The coronavirus in the United Kingdom Over 202 thousand people have died from COVID-19 in the UK, which is the highest number in Europe. The tireless work of the National Health Service (NHS) has been applauded, but the country’s response to the crisis has drawn criticism. The UK was slow to start widespread testing, and the launch of a COVID-19 contact tracing app was delayed by months. However, the UK’s rapid vaccine rollout has been a success story, and around 53.7 million people had received at least one vaccine dose as of July 13, 2022.

According to Cognitive Market Research, the Global Pneumococcal Vaccines Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

The Pneumococcal Vaccines market will expand significantly by XX% CAGR between 2024 and 2031.
The Pneumococcal Conjugate vaccine type accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
The usage of the Prevenar13 pneumococcal vaccine holds the largest market share compared to others.
By Distribution channel, the public health agencies hold the largest market share compared to others.
North-America region dominated the market and accounted for the highest revenue of XX% in 2022 and it is projected that it will grow at a CAGR of XX% in the future.

Factors Affecting the Growth of the Pneumococcal Vaccines Market

The rising cases of pneumonia are directly driving the demand for pneumococcal vaccines in the market.

Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae, as called pneumococcus. There are more than 100 subtypes and most of the subtypes can cause disease, but only a few produce the majority of invasive pneumococcal infections. Pneumonia is the single largest infectious cause of death in children worldwide. It causes more than a million hospitalizations and more than 50,000 deaths each year. (Source: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pneumonia/five-facts-you-should-know)

Around 4,000 cases of pneumococcal bacteremia occur every year in the United States. Bacteremia is the most common clinical presentation among children aged two years and younger, accounting for 70% of invasive disease in this group. Additionally, there are an estimated 2,000 cases of pneumococcal meningitis every year. Considering the criticality, pneumococcal disease is a serious disease that causes much sickness and death. Around, 30,300 cases and 3,250 deaths from invasive pneumococcal diseases are estimated to have occurred in the United States in 2019. (Source: https://www.immunize.org/wp-content/uploads/catg.d/p4213.pdf)

Furthermore, pneumonia accounts for around 14% of all deaths of children under 5 years old, killing nearly 740,180 children in 2019. (Source: https://www.who.int/news-room/fact-sheets/detail/pneumonia)

Certain medical concerns associated with the pneumococcal vaccine may restrict the Pneumococcal Vaccines Market growth.

Normally, most people who get a pneumococcal vaccine do not have any serious problems with it; however, with any medicines and vaccines, chances of being caught to certain side effects are always there. The side effects tend to be mild and go away on their own within a few days; however, some serious reactions might be possible.

Mild problems related to PCV15, PCV20, or PPSV23 can include Redness, swelling, pain, or tenderness where the shot was given, Fever or chills, Loss of appetite, Fussiness, Feeling tired, Headache, Muscle ache, or joint pain. These symptoms may lead people to avoid the vaccination, resulting in the restriction in the market growth. (Source: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html)

The most common side effects from pneumococcal vaccines are mild and last for 1 or 2 days. The chances of getting severe allergic reactions are very rare.; however, such independent risk factors can restrict the market growth for pneumococcal vaccines.

An innovative financial mechanism by the Pneumococcal Advance Market Commitment can be considered as an opportunity for vaccine makers to produce vaccines at affordable prices.

Each year, pneumococcal disease takes the lives of half a million children under five years of age, making it the leading vaccine-preventable cause of death among young children. The most effective estimate to prevent these deaths is to ensure access to effective, safe, and affordable vaccines. To make this happen, a pneumococcal Advance Market Commitment (AMC) has been designed to protect children against pneumococcal disease.

This financial commitment offers an innovative funding mechanism with the help of donor commitments, that can benefit vaccine makers to produce suitable and affordable vaccines for the world’s poorest countries accelerating the global roll-out of a vaccine against the world’s leading cause of c...

The mass rollout of a novel adult vaccine mid-pandemic required people worldwide to trust their governments' recommendations and vaccine delivery processes. Vaccine supply disruptions and political allegiances risked undermining this trust. We use data on the universe of Covid-19 vaccines in Sierra Leone to answer two questions. First, whether the relationship between support for Covid-19 vaccination and support for the party in power holds in a low-income environment (Sierra Leone) where trust in vaccines is traditionally high. Second, whether interruptions to vaccine supply reduced take-up of second doses. As with many other countries, we see a relationship between a region's long-term association with the party in power (proxied by ethnicity or language) and the take-up of the Covid-19 vaccine. A year since the start of the Covid-19 vaccination, Temne chiefdoms (associated with the main opposition) have an 18 percentage point lower take-up of Covid-19 adult vaccines compared to 52% take-up in Mende chiefdoms (associated with the ruling party). However, this is not a Covid-19 specific pattern. Temne areas had lower childhood vaccination rates pre-Covid even when the Temne-associated party is in power. This suggests take-up of Covid-19 vaccines in Sierra Leone was not politicized and not undermined by a lack of trust in the party in power. Moreover, we find that those who experienced vaccine stockouts when they were due for their second Covid-19 vaccine were just as likely as those not experiencing stockouts to eventually receive their second dose, even though they had to wait longer to receive it.This is the data and code accompanying the paper.

Illustrative quotes for individual barriers.

Illustrative quotes for structural barriers relating to health systems and service delivery.

As of June 4, 2022, China had administered about 780 million coronavirus COVID-19 vaccine booster doses, whereas over two billion doses of the boosters had been applied worldwide. Chinese residents who received two COVID-19 vaccine shots at least six months ago have been given booster doses since the end of October. The roll-out of boosters came after close to 80 percent of the country's population had been vaccinated.

Illustrative quotes for interpersonal and community barriers.

According to Cognitive Market Research, the global Covid-19 Therapeutics Market size will be USD 32542.5 million in 2025. It will expand at a compound annual growth rate (CAGR) of -15.20% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 13017.00 million in 2025 and will grow at a compound annual growth rate (CAGR) of -17.0% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 9762.75 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 7484.78 million in 2025 and will grow at a compound annual growth rate (CAGR) of -13.2% from 2025 to 2033.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1627.13 million in 2025 and will grow at a compound annual growth rate (CAGR) of -15.8% from 2025 to 2033.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 650.85 million in 2025 and will grow at a compound annual growth rate (CAGR) of -15.5% from 2025 to 2033.
The anti-viral category led the Covid-19 Therapeutics Market.

Market Dynamics of Covid-19 Therapeutics Market

Key Drivers for Covid-19 Therapeutics Market

Significant Investment in COVID-19 Treatment to Support the Market Growth

Investments in the creation of novel treatments for COVID-19 have been made by both public and commercial entities. This is partly because of how urgent the epidemic is and how important it is to have efficient treatments and vaccines. These expenditures have increased the commercial value of COVID-19 treatments and sped up the creation and accessibility of additional treatments. For the purpose of accelerating the development of COVID-19 treatments, governments and business groups have also established public-private collaborations. To hasten the public's access to certain medications and vaccines, governments have also granted Emergency Use Authorization (EUA). Consequently, these expenditures have been crucial to the quick development and rollout of novel COVID-19 therapies and vaccines. . This has lessened the pandemic's effects on international healthcare systems and economies. Furthermore, it is anticipated that this will continue to influence future advances in the COVID-19 Therapeutics industry.

New Coronavirus Variants Are Emerging to Accelerate the Growth

Since these novel viral strains would be less amenable to current treatments, there will probably be a large demand for medications that can effectively cure them. As pharmaceutical companies scramble to provide new medications and therapies to combat these novel variations, this is expected to increase the size of the COVID-19 Therapeutics market. Treatments and therapies would still be required to help those afflicted by the virus, including those with long-term impacts, even after the pandemic is under control. This is expected to keep fueling the market for COVID-19 treatments. Furthermore, governments and commercial organizations are expected to become more prepared for future pandemics as a result of the introduction of new viral varieties and the potential for future outbreaks.

Restraint Factor for the Covid-19 Therapeutics Market

High expenses associated with developing therapeutic medications and vaccinations, will Limit Market Growth

A major barrier to the market is the high cost of research and development (R&D) of COVID-19 vaccines and Therapeutics; the need for specialized infrastructure, advanced technology, and skilled personnel raises costs further; clinical trials, regulatory approvals, and manufacturing processes require substantial funding, which can delay the availability of new treatments; and the financial burden on pharmaceutical companies often results in higher prices, which limit accessibility, particularly in low- and middle-income countries. All of these factors work together to impede the rapid development and global distribution of effective COVID-19 Therapeutics, which slows market growth.

Market Trends in Covid-19 Therapeutics Market

Increasing use of oral antiviral medications

The market for COVID-19 treatments is seeing a significant increase with the increasing use of oral antiviral medications. These medications, such Merck's molnupiravir and Pfizer's Paxlovid, have seve...

Attitude on COVID-19 vaccination intention (hierarchical binary logistic regression).

Today, the Dow Jones Crude Oil Prices have shown a significant increase. Find out the key factors impacting the rise in oil prices, including OPEC+ production cuts, COVID-19 vaccine rollout, geopolitical tensions, and global economic indicators. Understand why crude oil prices are volatile and the implications for investors, energy companies, and governments worldwide.

As of January 23, 2021, Vermont had the highest Rt value of any U.S. state. The Rt value indicates the average number of people that one person with COVID-19 is expected to infect. A number higher than one means each infected person is passing the virus to more than one other person.

Which are the hardest-hit states? The U.S. reported its first confirmed coronavirus case toward the end of January 2020. More than 28 million positive cases have since been recorded as of February 24, 2021 – California and Texas are the states with the highest number of coronavirus cases in the United States. When figures are adjusted to reflect each state’s population, North Dakota has the highest rate of coronavirus cases. The vaccine rollout has provided Americans with a significant morale boost, and California is the state with the highest number of COVID-19 vaccine doses administered.

How have other nations responded? Countries around the world have responded to the pandemic in varied ways. The United Kingdom has approved three vaccines for emergency use and ranks among the countries with the highest number of COVID-19 vaccine doses administered worldwide. In the Asia-Pacific region, the outbreak has been brought under control in New Zealand, and the country’s response to the pandemic has been widely praised.

The COVID-19 vaccine rollout programme in Uganda was launched in March 2021 for priority groups: Healthcare Workers (HCWs), older persons (≥50 years), and persons with chronic conditions. Misinformation, distrust in healthcare systems, and cultural beliefs, pose significant challenges to vaccine uptake. We describe the social and structural factors affecting the uptake of COVID-19 vaccines among HCWs and older people in Uganda. Between September and October 2021, we conducted 33 in-depth interviews with 25 HCWs aged 21–63 years from three hospitals in central Uganda and eight older people from Wakiso district. Participant selection was purposive, based on sex, occupation, education, cadre of HCWs and vaccination status. We explored participants’ knowledge, beliefs, personal experiences, barriers, and facilitators to vaccine uptake as well as suggestions for future COVID-19 vaccine rollout. Interviews were audio-recorded, transcribed and translated into English, coded, and analysed by theme. Twenty-two of the 25 (88%) HCWs and 3 of the 8 (38%) older people had received at least one dose of the COVID-19 vaccine at the time of interview. The structural facilitating factors to vaccine uptake included access to correct information, fear of a risky work environment, and mandatory vaccination requirements especially for frontline HCWs. Age, chronic health conditions, and the fear of death were facilitating factors for older people. Misconceptions about COVID-19 vaccines and fear of side effects were common social barriers for both groups. Long distances to vaccination centres, vaccine stock-outs, and long queues at the vaccination centres were specific barriers for older people. The prerequisite of signing a consent form was a specific structural barrier for HCWs. Future roll out of new vaccines should have a comprehensive information dissemination strategy about the vaccines. Improved access to vaccines through community outreach, reliable vaccine supplies and addressing vaccine misinformation, may enhance COVID-19 vaccine uptake.

Canadians and people around the world are expecting the international research community to quickly develop and rollout safe vaccines and therapies to deal with the COVID-19 pandemic and return to a more normal life.

Economic conditions for exporters in New Zealand are expected to gradually improve as the global vaccine rollout continues.

According to Cognitive Market Research, the global Ultra cold Freezer Market size will be USD 584.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 233.84 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 175.38 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 134.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 29.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 11.69 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.
Upright Segment held the highest Ultra cold Freezer Market revenue share in 2024.

Market Dynamics of Ultra cold Freezer Market

Key Drivers for Ultra cold Freezer Market

Rising Demand for Biobanking and Genomics Research Boosts Ultra-Cold Freezer Market

The growing emphasis on biobanking and genomics research is significantly driving the demand for ultra-cold freezers. Biobanks need reliable storage solutions to preserve biological samples like blood, DNA, and tissues at ultra-low temperatures for extended periods. The rise in personalized medicine and the need for extensive genetic data to support research are fueling this demand. As maintaining sample integrity becomes more crucial, the adoption of advanced ultra-cold freezers is expected to increase, propelling market growth.

Expanding Pharmaceutical and Biotechnology Sectors Fueling Ultra-Cold Freezer Market Growth

The expansion of pharmaceutical and biotechnology sectors is a key driver for the ultra-cold freezer market. These industries require ultra-cold storage solutions for sensitive drug compounds, vaccines, and biological samples. With a global focus on developing new drugs and vaccines, particularly in response to emerging diseases, the demand for ultra-cold freezers is on the rise. Compliance with stringent regulatory standards also drives the adoption of high-performance storage solutions, ensuring the safety and efficacy of pharmaceutical products.?

Restraint Factor for the Ultra cold Freezer Market

High Initial Costs and Maintenance Expenses Hindering Market Growth

Despite the growing demand, the ultra-cold freezer market faces significant restraint due to high initial costs and ongoing maintenance expenses. Ultra-cold freezers are expensive to purchase, requiring substantial capital investment, which can be a barrier for smaller laboratories and research institutions. Additionally, these freezers consume a large amount of energy, leading to high operational costs. The need for regular maintenance to ensure optimal performance and prevent breakdowns further adds to the total cost of ownership, potentially limiting market growth in budget-constrained environments.

Impact of Covid-19 on the Ultra cold Freezer Market

The COVID-19 pandemic significantly impacted the ultra-cold freezer market by accelerating demand for storage solutions due to the global rollout of vaccines. Ultra-cold freezers became crucial for the storage and distribution of COVID-19 vaccines, which require temperatures as low as -70°C. This surge in demand highlighted the importance of reliable storage systems and led to increased investments in ultra-cold storage infrastructure. Additionally, the pandemic emphasized the need for robust cold chain logistics, driving innovations and expansions within the market to support both vaccine distribution and ongoing research in various sectors. Introduction of the Ultra cold Freezer Market

Ultra-cold freezers are advanced refrigeration systems designed to maintain extremely low temperatures, typically between -41°C and -150°C. These freezers are crucial for storing sensitive biological samples, drug compounds, and vaccines, ensuring their long-term stability and effectiveness. With a range of types, including upright, floor-standing, benchtop/und...

COVID-19 was first detected in Brazil on February 27, 2020, making it the first Latin American country to report a case of the novel coronavirus. Since then, the number of infections has risen drastically, reaching approximately 38 million cases by July 28, 2024. Meanwhile, the first local death due to the disease was reported in March 2020. Four years later, the number of fatal cases had surpassed 700,000. The highest COVID-19 death toll in Latin America With a population of more than 211 million inhabitants as of 2020, Brazil is the most populated country in Latin America. This nation is also among the most affected by COVID-19 in number of deaths, not only within the Latin American region, but also worldwide, just behind the United States. These figures have raised a debate on how the Brazilian government has dealt with the pandemic. In fact, according to a study carried out in May 2021, more than half of Brazilians surveyed disapproved of the way in which former president Jair Bolsonaro had been dealing with the health crisis. In comparison, a third of respondents had a similar opinion about the Ministry of Health. Brazil’s COVID-19 vaccination campaign rollout Brazil’s vaccination campaign started at the beginning of 2021, when a nurse from São Paulo became the first person in the country to get vaccinated against the disease. A few years later, roughly 88 percent of the Brazilian population had received at least one vaccine dose, while around 81 percent had already completed the basic immunization scheme. With more than 485.2 million vaccines administered as of March 2023, Brazil was the fourth country with the most administered doses of the COVID-19 vaccine globally, after China, India, and the United States.Find the most up-to-date information about the coronavirus pandemic in the world under Statista’s COVID-19 facts and figures site.

Learn about the significant fluctuations in crude oil prices over the past two years, influenced by global events and economic factors. Discover the impact of trade tensions, production cuts, COVID-19, and vaccine rollouts on the price of crude oil.